Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study.

Mathias JR, Clench MH, Abell TL, Koch KL, Lehman G, Robinson M, Rothstein R, Snape WJ

Digestive diseases and sciences1 Jun 1998Cited by 45 (Europe PMC)

PMID9635630DOI10.1023/a:1018888631286PepBankPUB-09635630

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanRandomized controlled trialEfficacy outcome
In menstruating women with functional bowel disease, leuprolide 7.5 mg improved abdominal pain versus placebo (P < 0.001).
In plain wordsIn women with functional bowel disease, leuprolide 7.5 mg improved abdominal pain versus placebo.
Peptide
Leuprolide
Outcome
DecreaseAbdominal pain
Study
n: not reported in source
Comparator
Placebo
Outcome group
Pain · Gastrointestinal
Studied dose
7.5 mg every four weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Patients in both Lupron Depot-treated groups showed consistent improvement in symptoms; however, only the Lupron Depot 7.5 mg group showed a significant improvement for abdominal pain and nausea compared to placebo (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of the present study was to expand the investigation to study similar patients (menstruating females) in a multicenter, double-blind, placebo-controlled, randomized study using Lupron Depot (which delivers a continuous dose of drug for one month), 3.75 mg (N = 32) or 7.5 mg (N = 33), or…
Report a problemFND-0963563001
02HumanRandomized controlled trialEfficacy outcome
In menstruating women with functional bowel disease, leuprolide 7.5 mg improved nausea versus placebo (P < 0.001).
In plain wordsIn women with functional bowel disease, leuprolide 7.5 mg improved nausea versus placebo.
Peptide
Leuprolide
Outcome
DecreaseNausea
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
7.5 mg every four weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Patients in both Lupron Depot-treated groups showed consistent improvement in symptoms; however, only the Lupron Depot 7.5 mg group showed a significant improvement for abdominal pain and nausea compared to placebo (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of the present study was to expand the investigation to study similar patients (menstruating females) in a multicenter, double-blind, placebo-controlled, randomized study using Lupron Depot (which delivers a continuous dose of drug for one month), 3.75 mg (N = 32) or 7.5 mg (N = 33), or…
Report a problemFND-0963563002
03HumanRandomized controlled trialEfficacy outcome
In menstruating women with functional bowel disease, leuprolide 3.75 mg did not significantly improve abdominal pain versus placebo.
In plain wordsIn women with functional bowel disease, leuprolide 3.75 mg did not significantly improve abdominal pain versus placebo.
Peptide
Leuprolide
Outcome
No significant changeAbdominal pain
Study
n: not reported in source
Comparator
Placebo
Outcome group
Pain · Gastrointestinal
Studied dose
3.75 mg every four weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Patients in both Lupron Depot-treated groups showed consistent improvement in symptoms; however, only the Lupron Depot 7.5 mg group showed a significant improvement for abdominal pain and nausea compared to placebo (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of the present study was to expand the investigation to study similar patients (menstruating females) in a multicenter, double-blind, placebo-controlled, randomized study using Lupron Depot (which delivers a continuous dose of drug for one month), 3.75 mg (N = 32) or 7.5 mg (N = 33), or…
Report a problemFND-0963563003
04HumanRandomized controlled trialEfficacy outcome
In menstruating women with functional bowel disease, leuprolide 3.75 mg did not significantly improve nausea versus placebo.
In plain wordsIn women with functional bowel disease, leuprolide 3.75 mg did not significantly improve nausea versus placebo.
Peptide
Leuprolide
Outcome
No significant changeNausea
Study
n: not reported in source
Comparator
Placebo
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
3.75 mg every four weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Patients in both Lupron Depot-treated groups showed consistent improvement in symptoms; however, only the Lupron Depot 7.5 mg group showed a significant improvement for abdominal pain and nausea compared to placebo (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of the present study was to expand the investigation to study similar patients (menstruating females) in a multicenter, double-blind, placebo-controlled, randomized study using Lupron Depot (which delivers a continuous dose of drug for one month), 3.75 mg (N = 32) or 7.5 mg (N = 33), or…
Report a problemFND-0963563004
05HumanRandomized controlled trialEfficacy outcome
In women with functional bowel disease, patient quality of life assessments were highly significant compared with placebo (P < 0.001) with leuprolide acetate; the abstract gives no direction.
In plain wordsIn women with functional bowel disease, quality of life assessments differed from placebo with leuprolide. The abstract gives no direction.
Peptide
Leuprolide
Outcome
Direction not reportedQuality of life
Study
n: not reported in source
Comparator
Placebo
Outcome group
Quality of life · Gastrointestinal
Studied dose
Dose not stated · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Patient quality of life assessments and global evaluations completed by both patient and investigators were highly significant compared to placebo (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of the present study was to expand the investigation to study similar patients (menstruating females) in a multicenter, double-blind, placebo-controlled, randomized study using Lupron Depot (which delivers a continuous dose of drug for one month), 3.75 mg (N = 32) or 7.5 mg (N = 33), or…
Report a problemFND-0963563005
06HumanRandomized controlled trialEfficacy outcome
In women with functional bowel disease, patient global evaluations were highly significant compared with placebo (P < 0.001) with leuprolide acetate; the abstract gives no direction.
In plain wordsIn women with functional bowel disease, patient global evaluations differed from placebo with leuprolide. The abstract gives no direction.
Peptide
Leuprolide
Outcome
Direction not reportedPatient global evaluation
Study
n: not reported in source
Comparator
Placebo
Outcome group
Global Assessment · Gastrointestinal
Studied dose
Dose not stated · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Patient quality of life assessments and global evaluations completed by both patient and investigators were highly significant compared to placebo (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of the present study was to expand the investigation to study similar patients (menstruating females) in a multicenter, double-blind, placebo-controlled, randomized study using Lupron Depot (which delivers a continuous dose of drug for one month), 3.75 mg (N = 32) or 7.5 mg (N = 33), or…
Report a problemFND-0963563006
07HumanRandomized controlled trialEfficacy outcome
In women with functional bowel disease, investigator global evaluations were highly significant compared with placebo (P < 0.001) with leuprolide acetate; the abstract gives no direction.
In plain wordsIn women with functional bowel disease, investigator global evaluations differed from placebo with leuprolide. The abstract gives no direction.
Peptide
Leuprolide
Outcome
Direction not reportedInvestigator global evaluation
Study
n: not reported in source
Comparator
Placebo
Outcome group
Global Assessment · Gastrointestinal
Studied dose
Dose not stated · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
Patient quality of life assessments and global evaluations completed by both patient and investigators were highly significant compared to placebo (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of the present study was to expand the investigation to study similar patients (menstruating females) in a multicenter, double-blind, placebo-controlled, randomized study using Lupron Depot (which delivers a continuous dose of drug for one month), 3.75 mg (N = 32) or 7.5 mg (N = 33), or…
Report a problemFND-0963563007
08HumanRandomized controlled trialEfficacy outcome
In women with functional bowel disease, both leuprolide groups had lower reproductive hormone levels versus placebo at week 16 (P < 0.001).
In plain wordsIn women with functional bowel disease, both leuprolide groups had lower reproductive hormone levels than placebo at week 16.
Peptide
Leuprolide
Outcome
DecreaseReproductive hormone levels at week 16
Study
n: not reported in source
Comparator
Placebo
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 or 7.5 mg every four weeks · intramuscular · 16 weeksAs given in this study (human).
Source sentences
Summary
All reproductive hormone levels significantly decreased for both Lupron Depot-treated groups by week 4 and were significantly different compared to placebo at week 16 (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of the present study was to expand the investigation to study similar patients (menstruating females) in a multicenter, double-blind, placebo-controlled, randomized study using Lupron Depot (which delivers a continuous dose of drug for one month), 3.75 mg (N = 32) or 7.5 mg (N = 33), or…
Report a problemFND-0963563009
09HumanNon-randomized trialEfficacy outcome
In women with functional bowel disease, reproductive hormone levels decreased significantly in both leuprolide groups by week 4.
In plain wordsIn women with functional bowel disease, reproductive hormone levels decreased from baseline in both leuprolide groups by week 4.
Peptide
Leuprolide
Outcome
DecreaseReproductive hormone levels by week 4
Study
n: not reported in source
Comparator
Baseline
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
3.75 or 7.5 mg every four weeks · intramuscularAs given in this study (human).
Source sentences
Summary
All reproductive hormone levels significantly decreased for both Lupron Depot-treated groups by week 4 and were significantly different compared to placebo at week 16 (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
The purpose of the present study was to expand the investigation to study similar patients (menstruating females) in a multicenter, double-blind, placebo-controlled, randomized study using Lupron Depot (which delivers a continuous dose of drug for one month), 3.75 mg (N = 32) or 7.5 mg (N = 33), or…
Report a problemFND-0963563008

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.